{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:24:03Z","timestamp":1777418643739,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[1999,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To characterize indinavir-associated rash using systematic data collection through postmarketing surveillance in a sample of HIV\/AIDS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN:<\/jats:title>\n                    <jats:p>HIV-infected patients identified through a medication counseling line who reported onset of a rash following initiation of indinavir therapy were included in this case series analysis. Pertinent information regarding onset, description, and management of rash; other medications initiated within two weeks of indinavir or rash onset; and medication allergy history was obtained through follow-up telephone contact. Patients were contacted weekly until the rash resolved or indinavir was discontinued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SETTING:<\/jats:title>\n                    <jats:p>Stadtlanders Drug Distribution Company, located in Pittsburgh, PA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Of the 110 patients identified and followed, 67% reported rash onset within two weeks of initiating indinavir therapy. The rash was initially localized in all 110 patients and subsequently spread to other areas of the body in 77% of the patients. The rash spread to the full body in 44% (49) of the patients. The rash was accompanied by pruritus in 86% of the patients, and the majority of patients (87%) were afebrile. Eighty-one patients received treatment with medications such as antihistamines or oral or topical corticosteroids. Fifty percent of patients receiving treatment for the rash reported that these medications were helpful in relieving rash symptoms. Fifty-nine percent of the patients continued indinavir therapy despite the occurrence of rash.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Results from this study suggest that indinavir-associated rash occurs within two weeks of initiation of therapy for the majority of patients. Typically, the rash is localized with subsequent spread and is associated with pruritus. The majority of patients are able to continue indinavir therapy despite the occurrence of rash.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.18160","type":"journal-article","created":{"date-parts":[[2004,3,11]],"date-time":"2004-03-11T17:08:19Z","timestamp":1079024899000},"page":"17-21","source":"Crossref","is-referenced-by-count":13,"title":["Characterization of Rash with Indinavir in a National Patient Cohort"],"prefix":"10.1177","volume":"33","author":[{"given":"Lidia K","family":"Gajewski","sequence":"first","affiliation":[{"name":"Lidia K Gajewski PharmD, Senior Clinical Manager HIV\/Druginformatics, Managed Health Care Division, Stadtlanders Pharmacy; Assistant Professor, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J","family":"Grimone","sequence":"additional","affiliation":[{"name":"Andrew J Grimone PharmD Student, School of Pharmacy, University of Pittsburgh; Chief Pharmacy Intern, Managed Health Care Division, Stadtlanders Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M","family":"Melbourne","sequence":"additional","affiliation":[{"name":"Kathleen M Melbourne PharmD, Clinical Assistant Professor of Pharmacy, College of Pharmacy, University of Rhode Island, Providence, RI; Consultant, Stadtlanders Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon J","family":"Vanscoy","sequence":"additional","affiliation":[{"name":"Gordon J Vanscoy PharmD MBA, Executive Vice President, Managed Health Care Division, Stadtlanders Pharmacy; Assistant Dean for Managed Care and Associate Professor, School of Pharmacy, University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1999,1,1]]},"reference":[{"key":"bibr1-aph.18160","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540480062040"},{"key":"bibr2-aph.18160","unstructured":"Mulligan K, Tai VW, Algren H, Chernoff DN, Lo JC, Schambelan M. Evidence of unique metabolic effects of protease inhibitors (abstract). Fifth Conference on Retrovirus and Opportunistic Infections, Chicago, IL, February 1\u20135, 1998."},{"issue":"24","key":"bibr3-aph.18160","first-page":"5","volume":"59","author":"McCaughan M","year":"1997","journal-title":"F-D-C Rep"},{"key":"bibr4-aph.18160","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199710001-00008"},{"key":"bibr5-aph.18160","volume-title":"Crixivan (indinavir sulfate)","year":"1996"},{"issue":"4","key":"bibr6-aph.18160","first-page":"7","volume":"2","author":"Roth JS","year":"1997","journal-title":"The PRN Notebook"},{"key":"bibr7-aph.18160","unstructured":"Race E, Reimann K, Letvin N, Japoul RA. Recurrence of trimethoprim\u2014 Sulfamethoxazole TMP-SMX hypersensitivity following initiation of protease inhibitor (PRI) in patients with advanced HIV-1 (abstract). Fourth Conference on Retrovirus and Opportunistic Infections, Washington, DC, January 22\u201326, 1997:164."},{"key":"bibr8-aph.18160","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-100-4-495"},{"key":"bibr9-aph.18160","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-100-5-663"},{"key":"bibr10-aph.18160","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-1-37"},{"key":"bibr11-aph.18160","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-4-280"},{"key":"bibr12-aph.18160","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)93402-U"},{"key":"bibr13-aph.18160","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.1.180"},{"key":"bibr14-aph.18160","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199504000-00004"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.18160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.18160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:44Z","timestamp":1777374464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.18160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["10.1345\/aph.18160"],"URL":"https:\/\/doi.org\/10.1345\/aph.18160","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}